Premium
Expression of CD176 (Thomsen‐Friedenreich antigen) on lung, breast and liver cancer‐initiating cells
Author(s) -
Lin WeiMing,
Karsten Uwe,
Goletz Steffen,
Cheng RuoChuan,
Cao Yi
Publication year - 2011
Publication title -
international journal of experimental pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.671
H-Index - 72
eISSN - 1365-2613
pISSN - 0959-9673
DOI - 10.1111/j.1365-2613.2010.00747.x
Subject(s) - cd44 , breast cancer , cancer research , cancer , antigen , lung cancer , immunohistochemistry , cancer stem cell , cancer cell , muc1 , liver cancer , pathology , biology , flow cytometry , medicine , immunology , cell , genetics
Summary The cancer‐initiating capacity of most malignant tumours is considered to reside in a small subpopulation of cells. Therapeutical interventions should target these cells rather than the tumour mass. Numerous studies have shown that the carbohydrate antigen structure CD176 (Thomsen‐Friedenreich antigen, core‐1) is present in many types of cancer and absent in normal adult human tissues. In this study, we assessed whether CD176 is co‐expressed with CD44 or CD133 [markers of cancer‐initiating cells (CIC)] in human lung, breast and liver carcinoma. A variety of human cancer cell lines and surgical specimens of these malignancies were examined. It was found that in most cases the majority of tumour cells stained strongly for CD44 by immunohistochemistry and flow cytometry, whereas CD133 expression was found on a smaller, but varying proportion of cells. Co‐expression of CD176 with CD44 was found at a surprisingly high percentage of cancer cells in vitro and in vivo . Co‐expression of CD176 with CD133 was also detected, although at a lower rate. Tamoxifen treatment of MDA‐435 breast cancer cells enhanced the CD44 + /CD176 + phenotype. Evidence is provided through a new sandwich solid‐phase enzyme‐linked immunosorbent assay (ELISA) suggesting that CD44 is a carrier molecule for CD176 not only in colorectal cancer as previously reported, but also in lung, breast and liver cancer. The expression of CD176 in CIC suggests that it may represent an effective target for tumour therapies.